Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Galapagos ( (GLPG) ).
On December 18, 2025, Galapagos reported topline data from two Phase 3-enabling trials of its selective TYK2 inhibitor GLPG3667, showing that the GALARISSO dermatomyositis study met its primary endpoint, with statistically significant improvement in Total Improvement Score at week 24 versus placebo using a pre-specified 10% significance level, alongside meaningful gains on multiple secondary disease-activity measures and a favorable safety and tolerability profile. In contrast, the GALACELA systemic lupus erythematosus trial did not reach statistical significance on its primary SRI-4 dose-response endpoint at week 32, although GLPG3667 showed numerical benefits over placebo on several secondary, particularly skin-related, outcomes; with Gilead temporarily waiving certain collaboration rights, Galapagos now plans to explore strategic options, including external partnerships, to accelerate further development of GLPG3667 in dermatomyositis and potentially other autoimmune indications, while awaiting full 48-week SLE data expected in 2026 to determine the future of that program.
The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Spark’s Take on GLPG Stock
According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.
Galapagos’ overall stock score reflects a challenging financial and operational landscape. The company’s strong cash position and strategic partnerships are positive, but are overshadowed by significant operating losses, poor valuation metrics, and technical indicators suggesting potential downward pressure. Investors should be cautious and monitor the company’s ability to execute its strategic transformation and improve financial performance.
To see Spark’s full report on GLPG stock, click here.
More about Galapagos
Galapagos NV is a Belgium-based biotechnology company listed on Euronext and NASDAQ that develops innovative small-molecule medicines, with a focus on inflammatory and autoimmune diseases. Its pipeline includes investigational therapies such as GLPG3667, a selective TYK2 inhibitor being studied in rare and severe immune-mediated disorders including dermatomyositis and systemic lupus erythematosus, targeting areas with high unmet medical need.
Average Trading Volume: 178,227
Technical Sentiment Signal: Sell
Current Market Cap: $2.03B
Learn more about GLPG stock on TipRanks’ Stock Analysis page.